Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Completed · Phase 1
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Some cancers become resistant to chemotherapy drugs. Combining mitomycin with a chemotherapy drug may reduce resistance to the drug and allow the cancer cells to be killed. PURPOSE: Phase I trial to study the effectiveness of mitomycin and mitoxantrone in treating patients with acute myelogenous leukemia and to determine whether mitomycin can reduce the cancer's resistance to chemotherapy.
Key facts
- Study ID
- NCT00003003
- Run by
- Dartmouth-Hitchcock Medical Center
- People needed
- 29
- Starts
- 1996-09-01
- Expected to finish
- 2000-08-01
- Last updated by the study team
- 2018-03-19
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.